TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03643276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Part of standard chemotherapy
Study: NCT04056754

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Subjects administered 5mg prednisone twice daily in 28-day cycle.
Study: NCT01814605

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infragluteal space group
Description: Sciatic Nerve Block Infragluteal group: Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The midpoint between these two structures is a rough non-binding estimate of the approximate location of the sciatic nerve. The sciatic nerve is usually found anterior (deep) to the gluteus maximus muscle and lateral to the origin of the biceps femoris muscle at the ischial tuberosity as well as medial to the greater trochanter.~The end point of nerve block in this group is obtaining a circumferential local anesthetic spread around the sciatic nerve.
Study: NCT03643276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: Pegaspargase
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone
Description: Part of standard chemotherapy
Study: NCT03817320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: Days 2, 15~Dose ≥ 1 year: 2,500 International units (IU)/m2/dose~≥ 6 months and \< 1 year: 2,000 IU/m2/dose~\< 6 months: 1,750 IU/m2/dose~Patient with allergic reaction to Pegaspargase can be given Erwinase IM/IV on Mon/Wed/Fri (or every other day per institutional standard) x 6 doses for each dose of Pegaspargase.~Dosing guideline for Erwinase:~* 1 year: 25,000 IU/m2/dose~* 6 months and \< 1 year: 20,000 IU/m2/dose~\< 6 months: 17,500 IU/m2/dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: Days 2, 15~Dose ≥ 1 year: 2,500 International units (IU)/m2/dose~≥ 6 months and \< 1 year: 2,000 IU/m2/dose~\< 6 months: 1,750 IU/m2/dose~Patient with allergic reaction to Pegaspargase can be given Erwinase IM/IV on Mon/Wed/Fri (or every other day per institutional standard) x 6 doses for each dose of Pegaspargase.~Dosing guideline for Erwinase:~* 1 year: 25,000 IU/m2/dose~* 6 months and \< 1 year: 20,000 IU/m2/dose~\< 6 months: 17,500 IU/m2/dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: Days 2, 15~Dose ≥ 1 year: 2,500 International units (IU)/m2/dose~≥ 6 months and \< 1 year: 2,000 IU/m2/dose~\< 6 months: 1,750 IU/m2/dose~Patient with allergic reaction to Pegaspargase can be given Erwinase IM/IV on Mon/Wed/Fri (or every other day per institutional standard) x 6 doses for each dose of Pegaspargase.~Dosing guideline for Erwinase:~* 1 year: 25,000 IU/m2/dose~* 6 months and \< 1 year: 20,000 IU/m2/dose~\< 6 months: 17,500 IU/m2/dose
Study: NCT03643276

Intervention type: DRUG
Group type: OTHER
Intervention: Tioguanin
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tioguanin
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tioguanin
Description: Part of standard chemotherapy
Study: NCT01814605

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subgluteal space group
Description: Subgluteal space group: The operator will identify the gluteus maximus and biceps femoris muscles at the level of the greater trochanter and ischial tuberosity and the infragluteal space.
Study: NCT04269694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medihoney dressing
Description: Medihoney is a mixture of two honeys derived from Australia and New Zealand containing glucose oxidase and Leptospermum compounds which contribute to its antibacterial activity.
Study: NCT03643276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tioguanin
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tioguanin
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tioguanin
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tioguanin
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tioguanin
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tioguanin
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tioguanin
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tioguanin
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: Tioguanin
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Part of standard chemotherapy
Study: NCT04269694

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medihoney dressing
Description: Medihoney is a mixture of two honeys derived from Australia and New Zealand containing glucose oxidase and Leptospermum compounds which contribute to its antibacterial activity.
Study: NCT03643276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Part of standard chemotherapy
Study: NCT03817320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Day 1~Dose ≥ 1 year: 60mg/m2/dose~≥ 6 months and \< 1 year: 48 mg/m2/dose~\< 6 months: 42mg/m2/dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Day 1~Dose ≥ 1 year: 60mg/m2/dose~≥ 6 months and \< 1 year: 48 mg/m2/dose~\< 6 months: 42mg/m2/dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Day 1~Dose ≥ 1 year: 60mg/m2/dose~≥ 6 months and \< 1 year: 48 mg/m2/dose~\< 6 months: 42mg/m2/dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Day 1~Dose ≥ 1 year: 60mg/m2/dose~≥ 6 months and \< 1 year: 48 mg/m2/dose~\< 6 months: 42mg/m2/dose
Study: NCT03643276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vindesine
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vindesine
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vindesine
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vindesine
Description: Part of standard chemotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: Erwinase
Description: Part of standard chemotherapy as substitute for PEG-L-Asparaginase in case of allergic reaction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase
Description: Part of standard chemotherapy as substitute for PEG-L-Asparaginase in case of allergic reaction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erwinase
Description: Part of standard chemotherapy as substitute for PEG-L-Asparaginase in case of allergic reaction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase
Description: Part of standard chemotherapy as substitute for PEG-L-Asparaginase in case of allergic reaction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase
Description: Part of standard chemotherapy as substitute for PEG-L-Asparaginase in case of allergic reaction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erwinase
Description: Part of standard chemotherapy as substitute for PEG-L-Asparaginase in case of allergic reaction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erwinase
Description: Part of standard chemotherapy as substitute for PEG-L-Asparaginase in case of allergic reaction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase
Description: Part of standard chemotherapy as substitute for PEG-L-Asparaginase in case of allergic reaction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase
Description: Part of standard chemotherapy as substitute for PEG-L-Asparaginase in case of allergic reaction
Study: NCT03817320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (IT)
Description: For patients with CNS 1 or CNS 2, on Days 1, 15, and 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (IT)
Description: For patients with CNS 1 or CNS 2, on Days 1, 15, and 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (IT)
Description: For patients with CNS 1 or CNS 2, on Days 1, 15, and 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (IT)
Description: For patients with CNS 1 or CNS 2, on Days 1, 15, and 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple IT (Methotrexate, Hydrocortisone, Cytarabine)
Description: For patients with CNS 3, on Days 1, 8, 15, 22, and 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple IT (Methotrexate, Hydrocortisone, Cytarabine)
Description: For patients with CNS 3, on Days 1, 8, 15, 22, and 29
Study: NCT03643276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase
Description: Part of standard chemotherapy as substitute for PEG-L-Asparaginase in case of allergic reaction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase
Description: Part of standard chemotherapy as substitute for PEG-L-Asparaginase in case of allergic reaction

Intervention type: DRUG
Group type: OTHER
Intervention: Erwinase
Description: Part of standard chemotherapy as substitute for PEG-L-Asparaginase in case of allergic reaction
Study: NCT02393547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: All subjects receive Varenicline
Study: NCT05197127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: exoskeleton-based gait training
Description: Gait training included dynamic over-ground walking (both self-selected and fast-paced), variable conditions of multi-directional walking, and training on ramps, stairs, and obstacle negotiation.
Study: NCT03339544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celebrex premedication
Description: celebrex (celecoxib) 200mg is a non-steroidal anti-infalmmatory drug with selective COX-2 inhibition.
Study: NCT02393547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Description: All subjects receive Lorcaserin
Study: NCT03018509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTE-451
Description: Active drug tablets containing JTE-451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTE-451
Description: Active drug tablets containing JTE-451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTE-451
Description: Active drug tablets containing JTE-451
Study: NCT03817320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple IT (Methotrexate, Hydrocortisone, Cytarabine)
Description: For patients with CNS 3, on Days 1, 8, 15, 22, and 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple IT (Methotrexate, Hydrocortisone, Cytarabine)
Description: For patients with CNS 3, on Days 1, 8, 15, 22, and 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: For patients with Down syndrome only, on Days 2, 9, 16, 23, and 30 (based on dates when IT Methotrexate or Triple IT is given)
Study: NCT03339544

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo is given as a tablet before initiation of endodontic treatment
Study: NCT01375699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: As prescribed by treating provider.
Study: NCT04296929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex Decongestive Physiotherapy
Description: Complete decongestive therapy (CDT), also called complex decongestive therapy, is an intensive program that combines many of the different treatment approaches, including bandaging, compression garments, manual lymphatic drainage, exercise, and self care.
Study: NCT03085342

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liver MRI
Description: Multiparametric Liver MRI including following sequences: DCE, DWI, MRE, precontrast flow measurement, fat quantification.
Study: NCT02721290

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve block using Ultrasound and neurostimulator

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral nerve block using Ultrasound

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5%
Description: Ropivacaine 0.5% (20cc total) will be injected for the performance of the block in the two arms of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Description: Ropivacaine 0.5% (20cc total) will be injected for the performance of the block in the two arms of the study.
Study: NCT03648502

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cognitive tests and hearing tests
Description: Several cognitive and hearing (peripheral and (central) auditory process) tests

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cognitive tests and hearing tests
Description: Several cognitive and hearing (peripheral and (central) auditory process) tests

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive tests and hearing tests
Description: Several cognitive and hearing (peripheral and (central) auditory process) tests
Study: NCT02239029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich plasma
Description: Platelet rich plasma (PRP) is a new and potential treatment for patients with kinds of musculoskeletal disorders.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The normal salin as the placebo intervention was injection in the other side of knee.
Study: NCT04315298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Single or multiple intravenous (IV) doses of sarilumab. Additional doses may be administered if the patient meets protocol defined criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Single or multiple intravenous (IV) doses of sarilumab. Additional doses may be administered if the patient meets protocol defined criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Single or multiple intravenous (IV) doses of sarilumab. Additional doses may be administered if the patient meets protocol defined criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Single or multiple intravenous (IV) doses of sarilumab. Additional doses may be administered if the patient meets protocol defined criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Single or multiple intravenous (IV) doses of sarilumab. Additional doses may be administered if the patient meets protocol defined criteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Single or multiple intravenous (IV) doses of sarilumab. Additional doses may be administered if the patient meets protocol defined criteria.
Study: NCT01602783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 11C Acetate Imaging
Description: Single scan
Study: NCT04315298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single or multiple intravenous (IV) doses of placebo to match sarilumab administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single or multiple intravenous (IV) doses of placebo to match sarilumab administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single or multiple intravenous (IV) doses of placebo to match sarilumab administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single or multiple intravenous (IV) doses of placebo to match sarilumab administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single or multiple intravenous (IV) doses of placebo to match sarilumab administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single or multiple intravenous (IV) doses of placebo to match sarilumab administration
Study: NCT01933399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inextensible LSO (stiff back support)
Description: Cotton/nylon canvas back support with velcro fasteners.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extensible LSO, a back support that is flexible
Description: Back support is constructed from lycra and neoprene with velcro fasteners.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Physician visit, physician advice, medications as determined by physician, over the counter medications, and physical therapy.
Study: NCT03474627

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-coated HA/TCP particles
Description: Maxillary sinus floor elevation and bone grafting with the use of biphasic hydroxyapatite and beta-tricalcium phosphate bone graft
Study: NCT02635139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breakfast skipping
Description: 18h fasting period in the morning
Study: NCT03474627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PLGA-coated HA/TCP particles
Description: Maxillary sinus floor elevation and bone grafting with the use of biphasic hydroxyapatite and beta-tricalcium phosphate bone graft with PLGA coating
Study: NCT01865136

Intervention type: OTHER
Group type: OTHER
Intervention: Medical Post Abortion Care
Description: Women with incomplete abortion is diagnosed and treated with misoprostol
Study: NCT03840681

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmentation
Description: non invasive technique to increase bone width and eliminate need for second surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Augmentation
Description: non invasive technique to increase bone width and eliminate need for second surgery
Study: NCT03844061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab decreases B-Cell survival and has been FDA approved for the treatment of systemic lupus erythematosus, another rheumatic autoimmune disease. Belimumab is a recombinant, fully human monoclonal antibody; it binds to the soluble human B lymphocyte stimulator (BLyS) with high affinity and inhibits its biologic activity. The background above provides a robust rationale for the investigation of belimumab in the treatment of dcSSc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituxan® (rituximab) is a genetically engineered IgG1 kappa chimeric murine/human monoclonal antibody containing murine light- and heavy-chain variable region sequences and human constant region sequences. The antibody reacts specifically with the CD20 antigen found on the surface of malignant and normal B cells, and established B cell lines. Studies have shown that rituximab binds via its Fc domain to human complement and lyses lymphoid B cell lines by complement dependent cytotoxicity through the induction of apoptosis and via antibody-dependent cell mediated cytotoxicity. Rituximab is approved by the U.S. Food and Drug Administration (FDA) to treat some types of cancer, rheumatoid arthritis and vasculitis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Subcutaneous Injection
Description: Normal Saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Infusion
Description: Normal Saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MMF
Description: MMF belongs to a group of medicines known as immunosuppressive agents. It is used with other medicines to lower the body's natural immunity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: MMF belongs to a group of medicines known as immunosuppressive agents. It is used with other medicines to lower the body's natural immunity.